Naltrexone Modification of Drinking Effects in a Subacute Treatment and Bar-Lab Paradigm: Influence of OPRM1 and Dopamine Transporter (SLC6A3) Genes

Alcoholism: Clinical and Experimental Research

Volumn 36, Issue 11, 2012, Pages 2000-2007

  Anton, Raymond F ^a   Voronin, Konstantin K ^a   Randall, Patrick K ^a   Myrick, Hugh ^a,b   Tiffany, Abraham ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b RALPH H JOHNSON VA MEDICAL CENTER   (United States)

Author keywords

Alcoholism; Drinking; Genetics; Medication; Opioid Receptors

Indexed keywords

ASPARAGINE; ASPARTIC ACID; DOPAMINE TRANSPORTER; NALTREXONE; OPIATE RECEPTOR; PLACEBO; PROTEIN SLC6A3; UNCLASSIFIED DRUG;

ADULT; ALCOHOL CONSUMPTION; ALCOHOL WITHDRAWAL; ALCOHOLISM; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DOUBLE BLIND PROCEDURE; DRINKING BEHAVIOR; DRUG DOSE COMPARISON; FEMALE; GENETIC DIFFERENCE; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR GENE; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; TREATMENT RESPONSE; VARIABLE NUMBER OF TANDEM REPEAT;

ADULT; AGED; ALCOHOL DRINKING; ALCOHOLISM; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; RECEPTORS, OPIOID, MU; SOCIAL ENVIRONMENT; TREATMENT OUTCOME; YOUNG ADULT;

ANIMALIA;

EID: 84868201122     PISSN: 01456008     EISSN: 15300277     Source Type: Journal    
DOI: 10.1111/j.1530-0277.2012.01807.x     Document Type: Article

References (41)

1. Anton R, Moak D, Latham P (1996) The obsessive compulsive drinking scale (OCDS): a new method of assessing outcome in alcoholism treatment studies. Arch Gen Psychiatry 53:225-231.
2. Anton RF (1996) New methodologies for pharmacologic treatment trials for alcohol dependence. Alcohol Clin Exp Res 20:3A-9A.
3. Anton RF, Drobes DJ, Voronin K, Durazo-Avizu R, Moak D (2004) Naltrexone effects on alcohol consumption in a clinical laboratory paradigm: temporal effects of drinking. Psychopharmacology 173:32-40.
4. Anton RF, Oroszi G, O'Malley SS, Couper DJ, Swift R, Pettinati HM, Goldman D (2008) An evaluation of μ-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the combined pharmacotherapies and behavioral interventions for alcohol dependence (COMBINE) study. Arch Gen Psychiatry 65:135-144.
5. APA (1994) Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Press, Washington, DC.
6. Barr CS, Chen SA, Schwandt ML, Lindell SG, Sun H, Suomi SJ, Heilig M (2010) Suppression of alcohol preference by naltrexone in the rhesus macaque: a critical role of genetic variation at the micro-opioid receptor gene locus. Biol Psychiatry 67:78-80.
7. Barr CS, Schwandt M, Lindell SG, Chen SA, Goldman D, Suomi SJ, Higley JD, Heilig M (2007) Association of a functional polymorphism in the {micro}-opioid receptor gene with alcohol response and consumption in male Rhesus Macaques. Arch Gen Psychiatry 64:369-376.
8. Bohn MJ, Krahn DD, Staehler BA (1995) Development and initial validation of a measure of drinking urges in abstinent alcoholics. Alcohol Clin Exp Res 19:600-606.
9. Dreher JC, Kohn P, Kolachana B, Weinberger DR, Berman KF (2009) Variation in dopamine genes influences responsivity of the human reward system. Proc Natl Acad Sci U S A 106:617-622.
10. Drobes DJ, Anton RF, Thomas SE, Voronin K (2003) A clinical laboratory paradigm for evaluating medication effects on alcohol consumption: naltrexone and nalmefene. Neuropsychopharmacology 28:755-764.
11. First MB, Spitzer RL, Gibbon M, Williams JBW (1997) Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition. New York State Psychiatric Institute, New York, NY.
12. Forbes EE, Brown SM, Kimak M, Ferrell RE, Manuck SB, Hariri AR (2009) Genetic variation in components of dopamine neurotransmission impacts ventral striatal reactivity associated with impulsivity. Mol Psychiatry 14:60-70.
13. Franklin TR, Lohoff FW, Wang Z, Sciortino N, Harper D, Li Y, Jens W, Cruz J, Kampman K, Ehrman R, Berrettini W, Detre JA, O'Brien CP, Childress AR (2009) DAT genotype modulates brain and behavioral responses elicited by cigarette cues. Neuropsychopharmacology 34:717-728.
14. Franklin TR, Wang Z, Li Y, Suh JJ, Goldman M, Lohoff FW, Cruz J, Hazan R, Jens W, Detre JA, Berrettini W, O'Brien CP, Childress AR (2011) Dopamine transporter genotype modulation of neural responses to smoking cues: confirmation in a new cohort. Addict Biol 16:308-322.
15. Fuke S, Suo S, Takahashi N, Koike H, Sasagawa N, Ishiura S (2001) The VNTR polymorphism of the human dopamine transporter (DAT1) gene affects gene expression. Pharmacogenomics J 1:152-156.
16. Gelernter J, Gueorguieva R, Kranzler HR, Zhang H, Cramer J, Rosenheck R, Krystal JH (2007) Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA cooperative study. Alcohol Clin Exp Res 31:555-563.
17. Gonzales RA, Weiss F (1998) Suppression of ethanol-reinforced behavior by naltrexone is associated with attenuation of the ethanol-induced increase in dialysate dopamine levels in the nucleus accumbens. J Neurosci 18:10663-10671.
18. King AC, Houle T, De Wit H, Holdstock L, Schuster A (2002) Biphasic alcohol response differs in heavy versus light drinkers. Alcohol Clin Exp Res 26:827-835.
19. Kornet M, Goosen C, Van Ree JM (1991) Effect of naltrexone on alcohol consumption during chronic alcohol drinking and after a period of imposed abstinence in free-choice drinking rhesus monkeys. Psychopharmacology 104:367-376.
20. Kranzler HR, Van Kirk J (2001) Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol Clin Exp Res 25:1335-1341.
21. Martin CS, Earleywine M, Musty RE, Perrine MW, Swift RM (1993) Development and validation of the biphasic alcohol effects scale. Alcohol Clin Exp Res 17:140-146.
22. Middaugh LD, Bandy A-LE (2000) Naltrexone effects on ethanol consumption and response to ethanol conditioned cues in C57BL/6 mice. Psychopharmacology 151:321-327.
23. Myrick H, Anton RF, Li X, Henderson S, Randall PK, Voronin K (2008) Effect of naltrexone and ondansetron on alcohol cue-induced activation of the ventral striatum in alcohol-dependent people. Arch Gen Psychiatry 65:466-475.
24. O'Brien CP (2008) Prospects for a genomic approach to the treatment of alcoholism. Arch Gen Psychiatry 65:132-133.
25. O'Malley SS, Krishnan-Sarin S, Farren C, Sinha R, Kreek MJ (2002) Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis. [see comment]. Psychopharmacology 160:19-29.
26. Ooteman W, Naassila M, Koeter MW, Verheul R, Schippers GM, Houchi H, Daoust M, Van Den Brink W (2009) Predicting the effect of naltrexone and acamprosate in alcohol-dependent patients using genetic indicators. Addict Biol 14:328-337.
27. Oslin DW, Berrettini W, Kranzler HR, Pettinati HM, Gelernter J, Volpicelli JR, O'Brien CP (2003) A functional polymorphism on the {micro}-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 28:1546-1552.
28. Ramchandani VA, Umhau J, Pavon FJ, Ruiz-Velasco V, Margas W, Sun H, Damadzic R, Eskay R, Schoor M, Thorsell A, Schwandt ML, Sommer WH, George DT, Parsons LH, Herscovitch P, Hommer D, Heilig M (2011) A genetic determinant of the striatal dopamine response to alcohol in men. Mol Psychiatry 16:809-817.
29. Ray LA, Barr CS, Blendy JA, Oslin D, Goldman D, Anton RF (2012) The role of the Asn40Asp polymorphism of the mu opioid receptor gene (OPRM1) on alcoholism etiology and treatment: a critical review. Alcohol Clin Exp Res 36:385-394.
30. Ray LA, Hutchison KE (2004) A polymorphism of the mu-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans. Alcohol Clin Exp Res 28:1789-1795.
31. Ray LA, Hutchison KE (2007) Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study. Arch Gen Psychiatry 64:1069-1077.
32. Schuckit M (1984) Subjective responses to alcohol in sons of alcoholics and control subjects. Arch Gen Psychiatry 41:879-884.
33. Skinner HA, Allen BA (1982) Alcohol dependence syndrome: measurement and validation. J Abnorm Psychol 91:199-209.
34. Sobell LC, Sobell MB, Leo GI, Cancilla A (1988) Reliability of a timeline method: assessing normal drinkers' reports of recent drinking and a comparative evaluation across several populations. Br J Addict 83:393-402.
35. Streeton C, Whelan G (2001) Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: a meta-analysis of randomized controlled trials. Alcohol Alcohol 36:544-552.
36. Sullivan JT, Sykora K, Schneiderman J, Naranjo CA, Sellers EM (1989) Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict 84:1353-1357.
37. Thomas SE, Drobes DJ, Voronin K, Anton RF (2004) Following alcohol consumption, nontreatment-seeking alcoholics report greater stimulation but similar sedation compared with social drinkers. J Stud Alcohol 65:330-335.
38. Vallender EJ, Ruedi-Bettschen D, Miller GM, Platt DM (2010) A pharmacogenetic model of naltrexone-induced attenuation of alcohol consumption in rhesus monkeys. Drug Alcohol Depend 109:252-256.
39. Van Der Zwaluw CS, Engels RC, Buitelaar J, Verkes RJ, Franke B, Scholte RH (2009) Polymorphisms in the dopamine transporter gene (SLC6A3/DAT1) and alcohol dependence in humans: a systematic review. Pharmacogenomics 10:853-866.
40. Voronin K, Randall P, Myrick H, Anton R (2008) Aripiprazole effects on alcohol consumption and subjective reports in a clinical laboratory paradigm-possible influence of self-control. Alcohol Clin Exp Res 32:1954-1961.
41. Watson TE (1989) Total body water and alcohol levels: updating the fundamentals, in Human Metabolism of Alcoholism (BATT CA ed), pp 41-66. CRC Press, Boca Raton.